KAM
STML

Kavi Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Kavi Asset Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-387,313
Closed -$5.93M – 12
2019
Q2 		$5.93M Sell
387,313
-292,887
-43% -$4.24M 4.91% 8
2019
Q1 		$8.74M Buy
+680,200
New +$7.69M 5.71% 5

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Kavi Asset Management's STML Position: Q3 2019 in Review

Kavi Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 387,313 shares — an estimated $5.93M sold.

Kavi Asset Management first reported a position in STML in Q1 2019 and held it in 2 quarters. The position peaked at $8.74M in Q1 2019. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • Kavi Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Kavi Asset Management sold 387,313 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $5.93M.
  • Kavi Asset Management first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 2 quarters.
  • Kavi Asset Management's Stemline Therapeutics, Inc. position peaked at $8.74M in Q1 2019.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on Kavi Asset Management's 13F filing for Q3 2019.